Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett's Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens
Curr Issues Mol Biol. 2023 May 29;45(6):4701-4715. doi: 10.3390/cimb45060299.ABSTRACTBarrett's esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malig...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Pietro Crispino Tiziana Ciarambino Mauro Giordano Source Type: research
Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett's Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens
Curr Issues Mol Biol. 2023 May 29;45(6):4701-4715. doi: 10.3390/cimb45060299.ABSTRACTBarrett's esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malig...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Pietro Crispino Tiziana Ciarambino Mauro Giordano Source Type: research
Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett's Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens
Curr Issues Mol Biol. 2023 May 29;45(6):4701-4715. doi: 10.3390/cimb45060299.ABSTRACTBarrett's esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malig...
Source: Current Issues in Molecular Biology - June 27, 2023 Category: Molecular Biology Authors: Pietro Crispino Tiziana Ciarambino Mauro Giordano Source Type: research
Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells
(Source: OncoTargets and Therapy)
Source: OncoTargets and Therapy - June 20, 2023 Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Therapeutic Effect of Polaprezinc on Reflux Esophagitis in the Rat Model
ConclusionsPolaprezinc has a significant therapeutic effect on RE in rats, which can reduce the levels of IL-8 and PGE2 and downregulate the expression of PI3K/Akt/mTOR signal pathway protein. The efficacy of polaprezinc in the treatment of reflux esophagitis is comparable to that of PPI, and the combination of them is more effective in the reflux esophagitis treatment. (Source: Digestive Diseases and Sciences)
Source: Digestive Diseases and Sciences - June 19, 2023 Category: Gastroenterology Source Type: research
Pharmacokinetics, Bioequivalence, and Safety of Esomeprazole Magnesium Enteric ‐Coated Capsules in Healthy Chinese Subjects
AbstractThis bioequivalence study is critically important for drug production. Recently, a local pharmaceutical company produced esomeprazole magnesium enteric-coated capsules, a major drug to help to eradicateHelicobacter pylori, but the bioequivalence is not well known. The present study aimed to evaluate the bioequivalence of the 2 esomeprazole magnesium enteric-coated capsules and their pharmacokinetics and safety in 3 biological equivalence trials: fasting, feeding, and mixing. The fasting and mixing trials used single-centered randomized, open-label, single-dose, 2-treatment, 2-period, and 2-sequence crossover design...
Source: Clinical Pharmacology in Drug Development - June 18, 2023 Category: Drugs & Pharmacology Authors: Juan Jin,
Cuiping Huang,
Changhai Zhu,
Wanni Feng,
Ang He,
Tuo Li,
Lina Wang,
Xiaolu Wang,
Xiali Rao,
Fangliang Gan Tags: Original Article Source Type: research
Patient Preparation with Esomeprazole Is Comparable to Ranitidine in Meckel Diverticulum Scintigraphy
Conclusion: This study confirms that esomeprazole, 40 mg, when administered intravenously 30 min before a Meckel scan, enhances the scan quality comparably to ranitidine. This procedure can be incorporated into protocols.PMID:37316300 | DOI:10.2967/jnmt.123.265558 (Source: Journal of Nuclear Medicine Technology)
Source: Journal of Nuclear Medicine Technology - June 14, 2023 Category: Nuclear Medicine Authors: Tessa F Ververs Anne-Fleur H Lobbezoo Monique G Hobbelink Arthur J Braat Source Type: research
